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Abstract
Introduction: Cholangiocarcinoma (CCA) often presents at an inoperable or an advanced stage in which 
complete resection is not possible. In such scenario, chemotherapy often is the only option to improve 
patient’s survival. Severe hyperbilirubinemia, often associated with higher risk of developing chemotherapy-
related adverse event, might complicates one’s decision in choosing chemotherapy regimen. Case Report: We 
present a case of 63-year-old post-operative CCA patient with residual mass and severe hyperbilirubinemia. 
The patient completed six cycles of gemcitabine (1000 mg/m2, day 1 and 8) and cisplatin (70 mg/m2, day 
1) every 3 weeks with tolerable side effect. No sign of residual tumor was observed on CT-Scan performed 
one-month post chemotherapy. Conclusion: Combination of cisplatin and gemcitabine may offer safe 
treatment option for post-operative residual CCA patient presenting with hyperbilirubinemia.
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Introduction
Cholangiocarcinoma (CCA) is one of 
the least commonly found type of cancer with 
worldwide incidence of less than 2/100,000 per 
year and 5-year survival rate of <10%. In the 
last two decades, the incidence and mortality 
rate of CCA have been increasing steadily.1,2 
Little is known about CCA in Indonesia. 
Epidemiological data of CCA in Indonesia 
currently doesn’t exist and detailed case report 
of CCA from Indonesia is very rare.
Case Report
A 63-year-old female presented with 
progressive jaundice for two months, along 
with pruritus, dark yellow colored urine, 
frequent diarrhea (approximately six times per 
Ibnu Purwanto1, Agus Barmawi2, Bambang Purwanto Utomo3, Ahmad Ghozali4 
Public  Health  and  Nursing,  Universitas  Gadjah  Mada/Dr.  Sardjito  General  Hospital,  Email: 
ibnupurwanto@ugm.ac.id.
3Radiology Department, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/
Dr. Sardjito General Hospital
2Digestive Surgery Department, Faculty of Medicine, Public Health, and Nursing, 
Universitas Gadjah Mada/Dr. Sardjito General Hospital
4Anatomical Pathology Department, Faculty of Medicine, Public Health and Nursing, 
Universitas Gadjah Mada/Dr. Sardjito General Hospital
Acta Interna The Journal of Internal Medicine, Volume 10, Number 2, December 2020: 109-112
109 
day), and epigastric pain over the same time 
period. She didn’t have significant past medical 
history. Family history included a daughter 
who passed away at the age of 42 years old due 
to breast cancer. 
Chest X-Ray showed no sign of lung 
and skeletal metastasis. Abdominal MSCT 
showed bile stone in common bile duct causing 
dilatation of intrahepatic and extrahepatic 
bile duct, hydrops of gallbladder, and 
cholecystolithiasis. An intraductal mass was 
also observed proximal to the bile stone. There 
was no sign of tumor invasion on pancreas, 
portal veins or hepatic arteries, suggesting 
stage IIA Cholangiocarcinoma. Laboratory 
examination showed total bilirubin of 15.9 
mg/dL, with direct bilirubin of 14.75 mg/dL. 
Exploratory laparotomy was performed 
along with cholecystectomy and exploration 
of common bile duct. Most of the tumor was 
removed but there was still tumor residue. 
Choledochoduodenal shunt was created to 
allow direct bile drainage into duodenum. Five 
bile stones were found during surgery, two in 
gallbladder and three in common bile duct. Post-
operative pathology showed mass in common 
bile duct and serous layer of gallbladder with 
histology of mucinous adenocarcinoma and 
signet ring cell carcinoma. The patient was 
discharged 12 days after surgery. Her symptoms 
improved upon discharge, although her jaundice 
remained. Her total bilirubin level on discharge 
was 6.01 mg/dL with direct bilirubin of 5.56 
mg/dL. Chemotherapy was initiated three weeks 
post-surgery as complete tumor removal was 
not possible. The patient received six cycles of 
gemcitabine (1000 mg/m2, day 1 and 8) and 
cisplatin (70 mg/m2, day 1) every 3 weeks with 
tolerable side effect. CT-Scan was performed one 
month after the completion of chemotherapy 
which showed no sign of residual tumor.
Discussion
Although some of CCA risk factors are 
well-understood, majority of CCA cases occur 
Figure 1. Left: CT-Scan of the abdomen at diagnosis, showing bile stone (red arrow) in common 
bile duct with a mass lesion proximal to the stone (blue arrow). Right: CT-Scan performed 1-month 
post chemotherapy, showing no sign of residual tumor (green arrow).
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sporadically. Some of established CCA risk 
factors include infection (HBV, HCV, liver 
flukes), chronic biliary tract inflammation 
(cholelithiasis, primary sclerosing cholangitis, 
liver cirrhosis, inflammatory bowel disease), 
congenital malformation (biliary-duct cysts) 
and toxins (thorium dioxide, smoking).1,3,4 
Some of CCA risk factors are thought to be 
geographically related, proven by variability 
of inter- and intra- continent incidence of 
CCA. Thailand, endemic area of Opisthorchis 
viverrini and Clonorchis sinensis infestation, 
has significantly higher prevalence of CCA 
compared to South East Asian countries in 
general (85/100,000 persons in northeastern 
Thailand compared to <2/100,000 persons 
in other south east Asian countries). Other 
endemic areas of liver fluke infestation such 
as China, Korea, and Japan also have higher 
prevalence of CCA (>2/100,000 persons).5
Mos t  o f  CCA pa t i en t s  r ema in 
asymptomatic until the tumor mass is 
big enough to cause pain (intrahepatic) 
or obstruct biliary drainage system which 
results in symptoms of obstructive jaundice 
(extrahepatic).6  MRI and MRCP are considered 
to be the best modalities to detect and stage 
CCA.7 CT-Scan is still widely used and is 
generally considered to provide acceptable but 
inferior result compared to MRI.8
Surgery is the mainstay treatment for 
CCA. Chemotherapy and radiotherapy are 
done in unresectable cases or when complete 
resection can’t be achieved. The role of 
neoadjuvant chemotherapy and radiotherapy 
are limited as CCA is generally not sensitive 
to these modalities.9 Should chemotherapy be 
prescribed, gemcitabine-based chemotherapy, 
either as single agent or in combination with 
other drugs, such as cisplatin, oxaliplatin, 
5-FU, or capecitabine present as viable 
options.10
Adjuvant chemotherapy was prescribed 
for this patient since complete surgical 
removal of the tumor mass was not possible. 
Combination of gemcitabine and cisplatin was 
chosen as this regimen showed the best response 
in previous reports.11,12 Liver transplant, the 
Figure 2. Left: CT-Scan of the abdomen at diagnosis, showing dilatation of intrahepatic bile duct 
(green arrow). Right: CT-Scan performed 1-month post chemotherapy, showing no sign of bile 
duct dilatation.
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best option for curative treatment, was not 
widely available in Indonesia thus was not an 
option for this patient. Before the initiation 
of chemotherapy, this patient’s total bilirubin 
level was 6.01 mg/dL with direct bilirubin level 
of 5.56 mg/dL, traditionally classified as high 
risk for chemotherapy initiation.13 We decided 
to go through with chemotherapy considering 
her excellent performance status. Furthermore, 
bilirubin level is not a reliable indicator of liver 
dysfunction severity in CCA patients, where 
the tumor mass might mechanically obstruct or 
constrict biliary ducts, resulting in obstructive 
jaundice.14 A complete response was observed 
after four cycles of gemcitabine and cisplatin, 
which is in concordance with the relatively 
high response rate of this regimen in CCA as 
reported in previous studies.11,12 This result is 
especially encouraging as Asian and Hispanic 
CCA patients are conventionally associated 
with worse prognosis.15
Conclusion
Chemotherapeutic regimen of cisplatin 
and gemcitabine may offer safe treatment 
option for post-operative residual CCA patient 
presenting with hyperbilirubinemia. 
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